Document is current
Any future updates will be listed below
-
Authors
Rabiei, Hamed https://orcid.org/0000-0001-6282-8020
Begnis, Marilyn https://orcid.org/0000-0001-6142-8113
Lemonnier, Eric
Ben-Ari, Yehezkel https://orcid.org/0000-0001-6208-8480
- License Information
-
More Information
Article History
Received: 26 June 2025
Revised: 12 December 2025
Accepted: 20 January 2026
First Online: 3 February 2026
Competing interests
: The study was funded by Neurochlore and BA-biomedical: 2 startups dedicated to treat Autism (neurochlore) and use IA and Machine Learning in this aim. Y Ben-Ari is CEO and shareholder of both startups. H Rabiei and M Begnis are paid by BA-Biomedical but are not shareholders. E Lemonnier has no conflict of interest.
: This paper is based on a re-analysis of a large multicentric phase 3 trial made by Servier (2021-2023) in 40 centers (Europe, Brazil, Australia) and all ethical issues and other requirements were met then and published (Crutel et al Journal of autism and neurodevelopmental disorders 2021 & Fuentes et al -Autism research 2023).
